Njord raises 8 MSEK to drive market introduction of Atle180

June 16, 2022
Gothenburg, Sweden

Njord Medtech® raises 8 MSEK in a rights issue co-led by Gobia Enterprises and ALMI Invest alongside Medtech business angels and existing investors.

With the given investment and new investors Njord Medtech have the capital needed to finance the market introduction of Atle 180 to the Swedish and Danish market during 2022/2023, and also gained seasonal medtech investors with international sales experience from the Patient Handling Market.

Jan Erik Smith, Board Member commented “Gobia Enterprises sees great potential in the innovative technology behind Atle that will contribute to a better situation for both caregivers and patients. We are positive that the technology is specifically adapted based on healthcare needs and to see the entrepreneurial spirit that characterizes the company. We look forward to the investment and to actively contribute to the company's development through our experience of commercializing medical devices internationally.

”At Radiology departments there can be up to 150,000 patient transfers done on a yearly basis. The transfers are conducted by up to five healthcare professionals, patients experience it as unpleasant, healthcare professionals derive stress and work-related injuries, and hospitals suffer from unbalanced throughput from the X-ray machines.

"With the novel solution Atle, Njord Medtech solves a large and well-known problem in healthcare. There is no similar product on the market why we see good potential for the company to succeed", says Lousie Investment Manager at Almi InvestLooking ahead Njord Medtech is targeting the whole European market with the novel medical device eyeing BeNeLux and UK&I as the upcoming markets when product-market fit is achieved in the initial Nordic introduction.

Jacob Ahrnstein, CEO of Njord Medtech commented, “In addition to the strong customer interest from leading University Hospitals in the Nordics, we now also have a solid base of leading industry investors. This investment positions both the company and the product Atle 180 to fulfill its purpose of improving the specialist care from both a patient and system perspective.”